| Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. | Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
Hara T, Uemoto R, Sekine A, Mitsui Y, Masuda S, Yamagami H, Kurahashi K, Yoshida S, Otoda T, Yuasa T, Kuroda A, Ikeda Y, Endo I, Honda S, Yoshimoto K, Kondo A, Tamaki T, Matsumoto T, Matsuhisa M, Abe M, Aihara KI., Free PMC Article | 08/4/2023 |
| Identification and characterization of a novel isoform of heparin cofactor II in human liver. | Identification and characterization of a novel isoform of heparin cofactor II in human liver.
Bano S, Fatima S, Ahamad S, Ansari S, Gupta D, Tabish M, Rehman SU, Jairajpuri MA. | 12/4/2021 |
| Loss of Heparin Cofactor is associated with insulin resistance . | The Role of Heparin Cofactor Ⅱ in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice.
Kurahashi K, Inoue S, Yoshida S, Ikeda Y, Morimoto K, Uemoto R, Ishikawa K, Kondo T, Yuasa T, Endo I, Miyake M, Oyadomari S, Matsumoto T, Abe M, Sakaue H, Aihara KI., Free PMC Article | 08/4/2018 |
| The plasma level of alpha2M was found positively correlated, while HCII level was negatively correlated with higher vulnerability of carotid plaques. Both proteins were efficient in differentiating stable and vulnerable carotid plaques. These provide potential new targets for the research of carotid plaque vulnerability. Plasma alpha2M and HCII may be potential biomarkers for evaluation of the vulnerability of carotid ... | Alpha-2-macroglobulin and heparin cofactor II and the vulnerability of carotid atherosclerotic plaques: An iTRAQ-based analysis.
Li J, Liu X, Xiang Y, Ding X, Wang T, Liu Y, Yin M, Tan C, Deng F, Chen L. | 06/10/2017 |
| We found that SERPIND1 may act as a potential oncogene in the development of ovarian cancer | Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells.
Zhu L, Guo Q, Jin S, Feng H, Zhuang H, Liu C, Tan M, Liu J, Li X, Lin B. | 03/18/2017 |
| Molecular modelling of HCII 1-75 predicted those portions of the acidic extension that had been previously visualized in crystal structures, and suggested that an alpha-helix found between residues 26 and 36 stabilizes one found between residues 61-67. | The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
Boyle AJ, Roddick LA, Bhakta V, Lambourne MD, Junop MS, Liaw PC, Weitz JI, Sheffield WP., Free PMC Article | 03/21/2015 |
| heparin co-factor II is a novel metastasis enhancer and may be used as a prognostic predictor for heparin treatment in non-small cell lung cancer | Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
Liao WY, Ho CC, Hou HH, Hsu TH, Tsai MF, Chen KY, Chen HY, Lee YC, Yu CJ, Lee CH, Yang PC. | 03/21/2015 |
| In this study, we demonstrate a previously unknown role for HCII in host defense. | Proteolytic activation transforms heparin cofactor II into a host defense molecule.
Kalle M, Papareddy P, Kasetty G, Tollefsen DM, Malmsten M, Mörgelin M, Schmidtchen A., Free PMC Article | 08/31/2013 |
| HCII potentiates the activation of vascular endothelial cells and the promotion of angiogenesis in response to hindlimb ischemia via an AMPK-eNOS signaling pathway. | Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.
Ikeda Y, Aihara K, Yoshida S, Iwase T, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Sata M, Akaike M, Kato S, Matsumoto T, Tamaki T., Free PMC Article | 01/5/2013 |
| Plasma heparin cofactor II activity was independently and inversely associated with the development of cardiac remodeling, including cardiac concentric change, left atrial enlargement and left ventricular diastolic dysfunction. | Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors.
Ise T, Aihara K, Sumitomo-Ueda Y, Yoshida S, Ikeda Y, Yagi S, Iwase T, Yamada H, Akaike M, Sata M, Matsumoto T. | 06/18/2011 |
| [REVIEW]HCII protects against vascular remodeling, including atherosclerosis | Heparin cofactor II attenuates vascular remodeling in humans and mice.
Aihara K. | 12/11/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium., Free PMC Article | 09/15/2010 |
| potential for oversulfated disaccharides in controlling HCII-regulated thrombin generation | Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.
Sarilla S, Habib SY, Kravtsov DV, Matafonov A, Gailani D, Verhamme IM., Free PMC Article | 04/19/2010 |
| These results suggest that HCII is in a position to inhibit thrombin in atherosclerotic lesions where thrombin can exert a proatherogenic inflammatory response. | Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.
Rau JC, Deans C, Hoffman MR, Thomas DB, Malcom GT, Zieske AW, Strong JP, Koch GG, Church FC., Free PMC Article | 01/21/2010 |
| Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. | Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Huang SS, Huang PH, Chen YH, Sung SH, Chiang KH, Chen JW, Lin SJ. | 01/21/2010 |
| Beta2-glycoprotein I (B2G1) protected thrombin against inactivation by HCII (heparin cofactor II)/heparin | Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies.
Rahgozar S, Giannakopoulos B, Yan X, Wei J, Cheng Qi J, Gemmell R, Krilis SA. | 01/21/2010 |
| Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance. | Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance.
Cunningham MA, Bhakta V, Sheffield WP. | 01/21/2010 |
| An asymptomatic Glu428Lys mutation affecting a conserved glutamate at the hinge (P17) of the reactive loop confirms the key structural role of the P17 glutamate in serpins. | Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis.
Corral J, Aznar J, Gonzalez-Conejero R, Villa P, Miñano A, Vayá A, Carrell RW, Huntington JA, Vicente V. | 01/21/2010 |
| after receiving stent for peripheral artery disease, patients with a high HCII activity had a 0.39-fold reduced risk for instent restenosis | High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting.
Schillinger M, Exner M, Sabeti S, Mlekusch W, Amighi J, Handler S, Quehenberger P, Kalifeh N, Wagner O, Minar E. | 01/21/2010 |
| role of basic amino acids of the A helix of heparin cofactor II in heparin- or dermatan sulfate-mediated thrombin inhibition. | Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
Hayakawa Y, Hirashima Y, Kurimoto M, Hayashi N, Hamada H, Kuwayama N, Endo S. | 01/21/2010 |
| structure analysis of the thrombin-heparin cofactor II complex | Molecular mapping of the thrombin-heparin cofactor II complex.
Fortenberry YM, Whinna HC, Gentry HR, Myles T, Leung LL, Church FC. | 01/21/2010 |
| HCII activity increases during pregnancy, and HCII levels are significantly decreased in women with severe pre-eclampsia. | Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.
Giri TK, Tollefsen DM., Free PMC Article | 01/21/2010 |
| Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote | Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
Mitchell JW, Church FC. | 01/21/2010 |
| The interactions of HCII with various heparins in solution competition experiments using SPR show that while calcium enhances this interaction, the activity of heparin-HCII complex against thrombin is not calcium dependent but can be enhanced by it. | Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance.
Zhang F, Wu Y, Ma Q, Hoppensteadt D, Fareed J, Linhardt RJ. | 01/21/2010 |